Enveda Biosciences closed an oversubscribed $150 million Series D financing round in September 2025, bringing total company funding to over $500 million235.
The financing will accelerate development of drugs inspired by nature to treat atopic dermatitis, asthma, obesity, and related immune diseases245.
This round was led by Premji Invest, with participation from top venture firms including Baillie Gifford, Kinnevik, Lingotto Investment Management, FPV, Socium Ventures, Dimension, and more13.
Enveda enrolled its first patient in a Phase Ib trial for its lead program ENV-294, targeting atopic dermatitis12.
Former Pfizer Chief Scientific Officer, Mikael Dolsten, has joined Enveda's board of directors12.
Enveda highlights nature as 'the lead chemist,' referencing drugs like aspirin and metformin, originally derived from plants2.
Sources:
1. https://www.thepharmaletter.com/biotechnology/enveda-further-accelerates-atopic-dermatitis-drive-with-financing
3. https://vcnewsdaily.com/enveda-biosciences/venture-capital-funding/qcrzndhtkf
4. https://www.biopharmadive.com/news/enveda-series-d-immune-obesity-dolsten-board/759080/
5. https://www.fiercebiotech.com/biotech/enveda-harvests-another-150m-advance-nature-inspired-drugs